Seattle Genetics, maker of the recently FDA approved antibody drug conjugate Adcetris for Hodgkin's lymphoma and anaplastic large cell lymphoma, has announced that it has begun a phase II trial exploring the efficacy of Adcetris in cancers other than the approved indications.
Because Adcetris is an anti-CD30 drug, it makes sense that the company would want to assess the drug against other cancers known to express CD30 on the cell surface.
According to Thomas C. Reynolds, M.D., Ph.D., Chief Medical Officer of Seattle Genetics, "There are reports in published literature of CD30 expression in multiple myeloma, several types of leukemia and solid tumors. Through both corporate-sponsored and investigator-sponsored trials, our development plan is designed to broadly evaluate the potential of Adcetris in many types of CD30-positive malignancies."
The company is therefore seeking to enroll patients with CD30-positive non-lymphoma malignancies who have failed, refused or have been deemed ineligible for standard therapy.
The trial's primary endpoint is characterization of the antitumor activity of Adcetris, and they expect to enroll 40 patients.
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...